BEIJING – Representatives from 100 Chinese pharma and biotech companies recently participated in a technology transfer conference, with "Chinese characteristics": In between name card speed exchanges, the organizers exhorted attendees to improve the quality of domestic drug innovation.
SHANGHAI – Glaxosmithkline plc, of London, has firmly denied rumors of sizable layoffs in its troubled China operation, reasserting its commitment to the country.
SHANGHAI – The all-important CFDA looks set to welcome a new commissioner into the fold. Bi Jingquan comes to the top spot with a long resume of government service, the bulk of which was spent at China's economic planning agency, the National Development Reform Commission (NDRC), where he specialized in pricing.
SHANGHAI – The all-important CFDA looks set to welcome a new commissioner into the fold. Bi Jingquan comes to the top spot with a long resume of government service, the bulk of which was spent at China's economic planning agency, the National Development Reform Commission (NDRC), where he specialized in pricing.
BEIJING – Representatives from 100 Chinese pharma and biotech companies recently participated in a technology transfer conference, with "Chinese characteristics": In between name card speed exchanges, the organizers exhorted attendees to improve the quality of domestic drug innovation.
SHANGHAI – China-based Ascentage Pharma Group said APG-1387 is set to enter phase I trials as a new chemical entity under the Chinese 1.1 drug classification, a special category for innovative therapies not approved in other countries. An oncology-focused biotech, Ascentage said it is the first in China to push forward an apoptosis candidate using a made-in-China molecule.
SHANGHAI – China-based Ascentage Pharma Group said APG-1387 is set to enter phase I trials as a new chemical entity under the Chinese 1.1 drug classification, a special category for innovative therapies not approved in other countries.
SHANGHAI – Hua Medicine Ltd. has received a nice endorsement from China's life science investors a month before the country's Spring Festival, closing $25 million in series B financing from some of the leading bio-focused venture capital firms, Frontline Bioventures and TF Capital. The latest financing was led by Ally Bridge Group, with all series A investors – Arch, Venrock, Fidelity, Wuxi Ventures and SAIL – chipping in for a second time.
SHANGHAI – Claiming a world-first, Chinese researchers have treated a spinal cord injury patient using a collagen scaffold loaded with mesenchymal stem cells in a trial to test the safety and efficacy of the procedure.
SHANGHAI – Claiming a world-first, Chinese researchers have treated a spinal cord injury patient using a collagen scaffold loaded with mesenchymal stem cells in a trial to test the safety and efficacy of the procedure.
